https://www.selleckchem.com/pr....oducts/Mubritinib-TA
functional echocardiographic features of cardiac amyloidosis had the worst prognosis in the TOPCAT study, but they benefitted similarly from spironolactone therapy. Future studies of mineralocorticoid receptor antagonists in patients with cardiac amyloidosis are warranted. The authors sought to examine the long-term cognitive outcome of patients with continuous flow left ventricular assist device (CF-LVAD). Data on long-term neurocognitive outcome in LVAD are limited. We examined the neurocognitive outcome of patients who rec
Like
Comment
Share